HomeCompareIGDFF vs PFE

IGDFF vs PFE: Dividend Comparison 2026

IGDFF yields 235.30% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IGDFF wins by $45.3K in total portfolio value
10 years
IGDFF
IGDFF
● Live price
235.30%
Share price
$0.85
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$94.9K
Annual income
$110.71
Full IGDFF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — IGDFF vs PFE

📍 IGDFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIGDFFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IGDFF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IGDFF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IGDFF
Annual income on $10K today (after 15% tax)
$20,000.47/yr
After 10yr DRIP, annual income (after tax)
$94.10/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $22,225.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IGDFF + PFE for your $10,000?

IGDFF: 50%PFE: 50%
100% PFE50/50100% IGDFF
Portfolio after 10yr
$72.2K
Annual income
$13,184.72/yr
Blended yield
18.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

IGDFF
No analyst data
Altman Z
3.4
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IGDFF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIGDFFPFE
Forward yield235.30%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%13.2%
Portfolio after 10y$94.9K$49.6K
Annual income after 10y$110.71$26,258.71
Total dividends collected$45.8K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: IGDFF vs PFE ($10,000, DRIP)

YearIGDFF PortfolioIGDFF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$22,465$11,764.98$9,153$693.39+$13.3KIGDFF
2$36,388$12,350.47$8,593$849.25+$27.8KIGDFF
3$48,283$9,348.07$8,336$1,066.78+$39.9KIGDFF
4$57,459$5,796.24$8,437$1,384.80+$49.0KIGDFF
5$64,705$3,223.27$9,013$1,875.40+$55.7KIGDFF
6$70,930$1,696.13$10,306$2,680.72+$60.6KIGDFF
7$76,764$868.84$12,820$4,101.38+$63.9KIGDFF
8$82,577$439.39$17,673$6,826.70+$64.9KIGDFF
9$88,578$220.87$27,543$12,591.86+$61.0KIGDFF
10$94,889$110.71$49,560$26,258.71+$45.3KIGDFF

IGDFF vs PFE: Complete Analysis 2026

IGDFFStock

IG Design Group plc designs, manufactures, and distributes celebrations, craft and creative play, stationery, gifting, and not for re-sale consumable products in the Americas, the United Kingdom, and internationally. It provides celebrations products, including greetings cards, gift wraps, Christmas crackers, gift bags, and partyware products, as well as gift accessories, such as tags, strings, ribbons, and bows; and gifting products comprise frames, albums, calendars and diaries, as well as food and non-food gifts. The company also offers ribbons and trims, sewing patterns, buttons, needlecrafts, and kids craft lines; stationery products, including pencils, pens, notebooks, pencil cases, clips, journals, etc. for use in education, commercial, and home settings; and bin liners, refuse sacks, food bags, and other collateral products, as well as paper twist handle bags. It serves retailers, other manufacturers and wholesalers of greetings products, service merchandisers, and trading companies. The company was formerly known as International Greetings plc and changed its name to IG Design Group plc in June 2016. IG Design Group plc was incorporated in 1978 and is based in Newport Pagnell, the United Kingdom.

Full IGDFF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this IGDFF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IGDFF vs SCHDIGDFF vs JEPIIGDFF vs OIGDFF vs KOIGDFF vs MAINIGDFF vs JNJIGDFF vs MRKIGDFF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.